Literature DB >> 27522979

Changes in Arterial Stiffness and N-terminal pro-brain natriuretic peptide Levels after Endovascular Repair of Descending Thoracic Aorta.

Konstantinos G Moulakakis1, Nikolaos P E Kadoglou2, Constantine N Antonopoulos3, Spyridon N Mylonas3, John Kakisis3, Ioannis Papadakis2, Petros Karakitsos4, Christos D Liapis3.   

Abstract

BACKGROUND: Limited data exist concerning the biomechanical and central hemodynamic changes induced by endograft implantation in the descending thoracic aorta. The aim of this prospective ongoing study was to evaluate changes in arterial stiffness, assessed by pulse wave velocity (PWV; m/sec), and N-terminal pro-brain natriuretic peptide (NT-proBNP; pg/mL) levels in patients undergoing endovascular repair of descending thoracic aorta (thoracic endovascular aortic repair [TEVAR]).
METHODS: Twenty-seven patients with thoracic aorta pathology who underwent elective TEVAR were included in the study. Blood samples were obtained preoperatively, 24 hr, 48 hr, and 6 months postoperatively, and serum levels of NT-proBNP were measured. PWV was determined before and 6 months after TEVAR. One-way analysis of variance by ranks was used to test the alterations in PWV (from baseline to 6 months) and NT-proBNP (along the 4 phases of evaluation). Post hoc analyses were appropriately performed.
RESULTS: We recorded an increase in values of NT-proBNP from baseline (median = 96.1, interquartile range [IQR] = 82.7-117.9) to 24 hr postoperative (median = 201.6, IQR = 82.8-425.9), 48 hr postoperative (median = 317.0, IQR = 102.5-1,479.5), and 6 months postoperative (median = 144, IQR = 82.8-276.4). The Kruskal-Wallis H test showed a statistically significant increase (x2(3) = 11.17, P = 0.01) in NT-proBNP from baseline (rank mean = 22.19) toward the postoperative time points of evaluation (24 hr postoperative: 35.17 [change: +12.9, P = 0.02]; 48 hr postoperative: 42.64 [change: +20.5, P < 0.001]; 6 month postoperative: 34.91 [change: +12.7, P = 0.03]). An increase in PWV values was recorded from baseline (median = 11.9, IQR = 10.0-13.5) to 6 months postoperatively (median = 13.9, IQR = 11.9-16.4). That change achieved statistically significant level [x2(1) = 4.86, P = 0.03], with an increase in mean rank PWV (+7.5).
CONCLUSIONS: Implementation of thoracic stent grafts may be associated with considerable increase of both arterial stiffness and NT-proBNP serum levels along time. Those results may indicate an adverse cardiac impact of TEVAR. However, the early and long-term effects of TEVAR on cardiovascular outcomes require further investigation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27522979     DOI: 10.1016/j.avsg.2016.04.025

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  Effect of endoskeleton stent graft design on pulse wave velocity in patients undergoing endovascular repair of the aortic arch.

Authors:  Daijiro Hori; Kei Akiyoshi; Koichi Yuri; Satoshi Nishi; Takao Nonaka; Takahiro Yamamoto; Yusuke Imamura; Harunobu Matsumoto; Naoyuki Kimura; Atsushi Yamaguchi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-08

2.  Commentary: Measuring the impact of thoracic endovascular aortic repair on the heart.

Authors:  Jennifer Worsham; Abe DeAnda
Journal:  JTCVS Tech       Date:  2020-01-13

Review 3.  TEVAR and EVAR, the unknown knowns of the cardiovascular hemodynamics; and the immediate and long-term consequences of fabric material on major adverse clinical outcome.

Authors:  Sherif Sultan; Yogesh Acharya; Osama Soliman; Juan Carlos Parodi; Niamh Hynes
Journal:  Front Surg       Date:  2022-08-30

4.  Changes in aortic pulse wave velocity of four thoracic aortic stent grafts in an ex vivo porcine model.

Authors:  Hector W L de Beaufort; Margherita Coda; Michele Conti; Theodorus M J van Bakel; Foeke J H Nauta; Ettore Lanzarone; Frans L Moll; Joost A van Herwaarden; Ferdinando Auricchio; Santi Trimarchi
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.